DiaCarta’s COVID-19 Test Ranks Top 10 Among All FDA EUA Tests Based on Limit of Detection
Richmond, California, September 2, 2020.
Based on evaluation of all the FDA EUA approved kits before July 27, 2020, DiaCarta’s QuantiVirusTM SARS-CoV-2 Multiplex Test ranks among the top 10 kits in terms of low limit of detection (LoD). DiaCarta is the top 6 company, after Perkin Elmer, Roche, Quest, RTA and BD Biosciences. The QuantiVirusTM SARS-CoV-2 Test, another RT-qPCR-based DiaCarta kit granted with FDA EUA, is top 20 on the list. The evaluation was conducted by MacKay et al. in Nature Biotechnology published on August 20.
Why is low LoD a big deal? According to Arnaout R et al., for every 10-fold increase in LoD, there is a 13% increase in false-negativity. This means tests with higher LoD significantly lower the test sensitivity, although clinical sensitivity and specificity are both over 95% for all 157 tests on the list. Surprisingly, the LoD for these tests spans 5 orders of magnitude from 0.009 to more than 100 copies per mL of sample.
“We are proud to have two viral RNA tests approved by the FDA EUA and CE-marked, both of which are highly sensitive,” Said Dr. Ramanathan Vairavan, Senior Vice President, Commercial Operations at DiaCarta, Inc. “These tests are critical for COVID-19 infection screening as we reopen the economy.”
In addition, DiaCarta has also developed the QuantiVirusTM Anti-SARS-CoV-2 IgG test, which is also filed with FDA and is CE-marked. This sensitive antibody test, once approved by FDA EUA, will add great value identifying potential blood donors for COVID-19 plasma therapy authorized by FDA EUA on August 23, although the risk reduction from the therapy may be relative rather than absolute, according to Dr. Steven Hahn, the FDA commissioner.
To help speed up COVID-19 screening, DiaCarta has validated these tests at our own CLIA lab. With three types of sample collection kits available (nasal, oral, and saliva), DiaCarta offers seamless COVID-19 testing services for healthcare providers, public health departments, businesses, and schools.
About DiaCarta:
DiaCarta is a molecular diagnostics company that has developed innovative technologies to transform patient care. Its novel XNA technology provides ultra-sensitivity for ColoScape™ Colorectal Cancer Test. Powered by SuperbDNA™ technology, the company has developed revolutionary RadTox™ test that personalizes radiation therapy to mitigate adverse events. Based in Richmond, California, the company is ISO certified, GMP-compliant and offers CLIA certified laboratory services.
DiaCarta’s Novel XNA Technology Rapidly Detects Raging New SARS-CoV-2 Variants
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced the publication of a study entitled “A Rapid SARS-CoV-2 Variant Detection by Molecular-Clamping Based RT-qPCR” in MedRxiV that demonstrates the enhanced sensitivity and specificity using its proprietary XNA based Molecular Clamping Technology that uses innovative synthetic Xenonucleic acid molecular oligomers (XNA) that hybridize with target wild-type DNA sequences, acting as molecular clamps, to enable the accurate amplification of mutant sequences only, using quantitative real-time polymerase chain reactions (qPCR).
DiaCarta Announces Publication in Nature Scientific Reports Demonstrating cfDNA Biomarker Algorithm Predicts Response and Outcome of Chemotherapy
DiaCarta Inc., a precision molecular diagnostics company with proprietary technologies for the development of novel liquid biopsy oncology tests, announced today the publication of a study in Nature Scientific Reports that demonstrates that DiaCarta’s cfDNA biomarker algorithm could function as a prognostic biomarker and efficacy predictor for non-small cell lung cancer (NSCLC) patients.
FDA Report: DiaCarta COVID-19 Tests Rank Top 3 Among FDA SARS-CoV-2 Reference Panel Tests
According to the recent FDA SARS-CoV-2 Reference Panel Comparative Data released on September 15, among all the FDA EUA tests with returned results, DiaCarta’s QuantiVirusTM SARS-CoV-2 Test and QuantiVirus™ SARS-CoV-2 Multiplex Test both rank within the top 3 for product sensitivity.
DiaCarta Receives Regulatory COFEPRIS Approval in Mexico & ICMR Approval in India for its FDA EUA Approved QuantiVirus™ SARS-CoV-2 Test
DiaCarta Inc., a precision molecular diagnostics company with a unique, patented XNA technology platform for the development of novel liquid biopsy tests, announced today that its QuantiVirus™ SARS-CoV-2 test has been approved for distribution in Mexico.
DiaCarta SARS-CoV-2 Test Detecting 3 Viral Genes Receives US FDA Emergency Use Authorization & Test Manufacturing Expanded to 500K COVID-19 Tests/Week
DiaCarta Inc, a precision molecular diagnostic company in CA, announced Thursday the US FDA granted Emergency Use Authorization for DiaCarta’s proprietary QuantiVirus™ PCR diagnostic (Dx) test specifically detecting three different genes of SARS-CoV-2, the virus causing the COVID-19 pandemic. DiaCarta recently expanded manufacturing capacity to 500,000 tests per week and is planning to expand to even larger (4x) scale manufacturing to meet the increasing demand for PCR tests to monitor COVID-19.